UCB 2019 Financial Results: Strong growth while preparing for the ...
(WorldNews Belgium)

UCB recorded a year of strong delivery and growth in 2019, as you can see from our latest financial results. The performance of some of our core products was so strong last year that it has prompted us to update the peak sales guidance for our two key products in both immunology and neurology. At the same time, thanks to our promising late-stage pipeline and the pending acquisition of Ra Pharma...